Printer Friendly

Model-Oriented Knowledgebases (KBs) Can Accelerate the Drug Discovery Process by Reducing the Time Spent on These Processes.

DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c31585) has announced the addition of Knowledge Management Tools for Drug Discovery to their offering.

Pharmaceutical companies are investing in new R&D technologies in the hope that they will accelerate research and, ultimately, improve both productivity and profitability. Before these technologies can boost profitability, however, the data they produce must be converted into knowledge that can be applied to the development of new drugs. A significant bottleneck in this process is the long practiced, but inefficient, method that scientists use to integrate new data and information with existing knowledge--i.e., the paper-based notebook.

In this report, we examine how knowledge management principles can be used to identify and apply computational tools, including electronic laboratory notebooks and knowledgebases, to synthesize scientific knowledge.

Business Implications

--Investment in data-intensive technologies has contributed significantly to the precipitous rise in pharmaceutical R&D costs, but it has not increased the number of new drug launches. A significant bottleneck in deriving value from data produced by these technologies is the inefficient method that scientists use to integrate new data with existing knowledge. Computational knowledge management tools can aid researchers in accomplishing this task more efficiently.

--A primary source of existing knowledge in drug discovery organizations is laboratory notebooks. Retrieving information from paper-based notebooks is a clear bottleneck in generating new knowledge. Because of their searchability, electronic laboratory notebooks (ELNs) will enhance knowledge utilization. User adoption is one of the main hurdles to implementing ELNs; developers must therefore address concerns such as flexibility, ease of use, privacy, and authentication.

--Integration of information from scientific literature is another bottleneck on the path from data to knowledge. Assistance in identifying relevant literature and integrating it with analyses should improve the efficiency of decision making. Model-oriented knowledgebases (KBs) can accelerate the drug discovery process by reducing the time spent on these processes.

--Recent generations of ELNs interface with most data-generating instrumentation and data warehouses. These ELNs may eventually provide single-interface access to both data and knowledge. We expect that ELNs will evolve into portals that scientists can access to conduct research activity.

--Although model-oriented KBs are currently used for target identification and validation, researchers are likely to find high-value uses in areas such as lead compound selection, toxicology, and clinical development. These uses may help companies reduce clinical failure rates and expand indications for existing approved drugs.

Companies Mentioned:

--CambridgeSoft

--Collaborative Electronic Notebook Systems Association (CENSA)

--Contur Technology

--LabBook

--Teranode

For more information visit http://www.researchandmarkets.com/reports/c31585 Decision Resources
COPYRIGHT 2006 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Jan 30, 2006
Words:423
Previous Article:Kodak's 4th-Quarter Sales Rise 12% to $4.197 Billion; Full-Year Digital Sales Exceed Traditional Sales for the First Time; 4th-Qtr Digital Sales...
Next Article:Maptuit Appoints MapQuest Executive as New Sr. V.P. of Sales; Industry Readies as Former MapQuest Executive Joins Maptuit.
Topics:


Related Articles
RESEARCH PROJECTS UTILIZE COMPUGEN'S GENCARTA DATABASE.
ARIAD and Zygogen Establish Zebrafish Genomics Collaboration.
BIACORE'S NEW ADVANCED SYSTEM SET TO DRAMATICALLY REDUCE DRUG DISCOVERY AND DEVELOPMENT BOTTLENECKS; BIACORE LAUNCHES NEW HIGH PERFORMANCE ANALYTICAL...
Discovery Partners International Announces Major Chemistry Collaboration With Merck.
Syrrx Achieves First Research Milestone in Cubist Collaboration.
Aventis Pharmaceuticals Selects SciTegic's Pipeline Pilot for Global Cheminformatics Applications.
Pharsight's Model-Based Drug Development Methodology to be Used by Aventis Pharma in Global Drug Development.
Japan's TV broadcasters trail in race to go digital. (Upfront).
UPSTATE GROUP/CXR BIOSCIENCES DEVELOPING IN VITRO SCREENS.
Mochida Pharmaceutical Adopts British Inpharmatica's In-silico ADME Suite, Admensa Interactive.

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters